Using data from the Dutch nationwide congenital corvitia (CONCOR) registry, we determined sex-specific long-term survival of, and morbidity in adult ASD2 patients.Survival was compared with that of the general Dutch population.
Median survival was 79.7 years for men and 85.6 years for women with ASD2.
Compared with the age- and sex-matched general population, survival was lower for male, but equal for female patients ( = 0.015 and 0.766, respectively).
Both codes are used for ASD2; primum and sinus venosus defects have separate codes.
Patients with a coexistent cleft mitral valve or anomalous pulmonary venous connections were excluded, to reduce both heterogeneity and the chance of including incorrectly coded primum and sinus venosus defects. For each patient date of birth, sex, CONCOR inclusion date, mortality, date of death, referral centre, date and mode of ASD closure, date of pacemaker or implantable cardioverter defibrillator (ICD) implantation, and data on the first occurrence and corresponding date of adverse events were obtained from CONCOR.
Department of Cardiology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.
Tel: 31 , Fax: 31 , Email: [email protected] The identification of sex differences in the prognosis of adults with a secundum atrial septal defect (ASD2) could help tailor their clinical management, as it has in other cardiovascular diseases.
However, estimates of survival after corrective treatment are not readily applicable to the entire ASD2 population.
Moreover, the influence of sex on long-term morbidity and survival of ASD2 patients is unknown.
We investigated whether disparity between the sexes exists in long-term outcome of adult ASD2 patients.
Patients with ASD2 classified as the primary defect were selected from the Dutch national registry of adult congenital heart disease.
Using the Dutch CONCOR database, we prospectively assessed survival, as well as cumulative incidence and risk of clinical events in ASD2 patients.